An evaluation of both serum Klotho/FGF-23 and apelin-13 for detection of diabetic nephropathy

Simple item page
dc.contributor.authorOzdemir N.
dc.contributor.authorToraman A.
dc.contributor.authorTaneli F.
dc.contributor.authorYurekli B.S.
dc.contributor.authorHekimsoy Z.
dc.date.accessioned2024-07-22T08:02:20Z
dc.date.available2024-07-22T08:02:20Z
dc.date.issued2023
dc.description.abstractPurpose: The aim of our study is to evaluate whether serum Klotho/FGF-23 and apelin-13 can be used as new biomarkers for detection of development of nephropathy. Methods: In this cross-sectional study, 88 type 2 diabetes mellitus (T2DM) patients and 38 healthy controls were included. The mean duration of T2DM was 11.4 ± 9.7 years. T2DM individuals were categorized into two groups as group 1 with e-GFR < 60 mL/min/1.73 m2 and group 2 with e-GFR > 60 mL/min/1.73 m2. They were also divided into two groups according to their 24 h urine albumin levels, classifying them as follows: normoalbuminuria if less than 30 mg/day and albuminuria if more than 30 mg/day. Results: Mean serum Klotho levels in the T2DM group were observed to be significantly higher than in the control group. Serum apelin-13 levels were observed to be significantly lower in the T2DM group compared to the control group (p < 0.001). In the diabetic group, apelin-13 levels were positively correlated with age, waist circumference, and albuminuria while they were negatively correlated with e-GFR. Apelin-13 levels were seen to be significantly higher in group 1 (p < 0.001). Conclusion: Apelin-13 levels were found to be significantly higher in individuals with diabetic nephropathy than in those without diabetic nephropathy. In the diabetic group, a significant relationship was detected between apelin-13 levels and albumin excretion. Based on these findings, we consider that serum Klotho and apelin-13 levels may have a protective effect on diabetic nephropathy and can additionally be used as a biomarker to predict diabetic nephropathy. © 2023, The Author(s), under exclusive licence to Hellenic Endocrine Society.
dc.identifier.DOI-ID10.1007/s42000-023-00464-4
dc.identifier.issn11093099
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11804
dc.language.isoEnglish
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.subjectAlbumins
dc.subjectAlbuminuria
dc.subjectApelin
dc.subjectBiomarkers
dc.subjectCross-Sectional Studies
dc.subjectDiabetes Mellitus, Type 2
dc.subjectDiabetic Nephropathies
dc.subjectGlucuronidase
dc.subjectHumans
dc.subjectalbumin
dc.subjectapelin
dc.subjectapelin 13
dc.subjectbiological marker
dc.subjectfibroblast growth factor 23
dc.subjectklotho protein
dc.subjectunclassified drug
dc.subjectalbumin
dc.subjectapelin
dc.subjectapelin-13 peptide
dc.subjectbeta glucuronidase
dc.subjectbiological marker
dc.subjectadult
dc.subjectage
dc.subjectalbumin urine level
dc.subjectalbuminuria
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjectcross-sectional study
dc.subjectdiabetic nephropathy
dc.subjectdiabetic patient
dc.subjectdisease duration
dc.subjectdisease marker
dc.subjectenzyme linked immunosorbent assay
dc.subjectestimated glomerular filtration rate
dc.subjectfemale
dc.subjecthuman
dc.subjectlaboratory test
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectprotein blood level
dc.subjectprotein function
dc.subjectTurkey (republic)
dc.subjectuniversity hospital
dc.subjectwaist circumference
dc.subjectdiabetic nephropathy
dc.subjectnon insulin dependent diabetes mellitus
dc.subjecturine
dc.titleAn evaluation of both serum Klotho/FGF-23 and apelin-13 for detection of diabetic nephropathy
dc.typeArticle

Files

Collections

Scopus Koleksiyonu